Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can WhatsApp alerts tame blood sugar swings in kids with type 1 diabetes?

NCT ID NCT07828106

Disease control Sponsor: Sheba Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers at Sheba Medical Center are studying a tele-diabetes remote monitoring system for children and teens with type 1 diabetes. The system analyzes real-time glucose data from continuous monitors and sends automated WhatsApp alerts when it detects high or low patterns. The trial compares participants who receive these alerts plus hybrid follow-up with those who receive standard care, looking at measures like time in range, HbA1c, quality of life, and emergency room visits. About 100 young people who already use continuous glucose monitors and closed-loop insulin pumps take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a tele-diabetes remote monitoring system that sends automated WhatsApp alerts about glucose trends
What this could lead to
If it works, this approach could give families a low-cost way to catch dangerous glucose swings between clinic visits and reduce emergency trips for diabetic ketoacidosis or severe hypoglycemia.
What could go wrong
The trial is small and tests a messaging tool rather than a new medicine, so any benefit may come from extra attention rather than the alerts themselves. Families must already use continuous glucose monitors and closed-loop insulin pumps, which limits who could use it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must have a confirmed diagnosis of Type 1 Diabetes Mellitus (T1DM). * Participants must use Dexcome Continuous Glucose Monitoring (CGM) * Must have access to a smartphone capable of receiving WhatsApp messages. * Participants must use a closed-loop insulin pump system (also known as an artificial pancreas system) omnipod DIY or Tandem. Exclusion Criteria: * Participants who are not using Dexcome Continuous Glucose Monitoring (CGM) and a closed-loop insulin pump system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 1 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 1 diabetes Mobile health Mobile health platform Mobile health technology (mhealth) Telemedicine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sheba medical center

    RECRUITING

    Ramat Gan, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.